Iterum Therapeutics (NASDAQ:ITRM) Rating Lowered to Hold at Zacks Investment Research

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company’s product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. “

A number of other analysts have also recently weighed in on ITRM. HC Wainwright cut Iterum Therapeutics from a “buy” rating to a “neutral” rating and set a $0.69 price target on the stock. in a research report on Monday, July 26th. Gabelli upgraded Iterum Therapeutics from a “sell” rating to a “hold” rating and set a $0.70 price target on the stock in a research report on Tuesday, July 27th. Finally, G.Research cut Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 2nd. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $0.91.

Shares of ITRM opened at $0.56 on Wednesday. The company has a market capitalization of $101.99 million, a P/E ratio of -0.34 and a beta of 1.22. Iterum Therapeutics has a one year low of $0.45 and a one year high of $3.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.80 and a current ratio of 2.80. The stock has a 50-day moving average price of $0.74 and a 200 day moving average price of $1.20.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. As a group, equities research analysts forecast that Iterum Therapeutics will post -0.16 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC boosted its stake in Iterum Therapeutics by 3,304.5% during the 2nd quarter. Millennium Management LLC now owns 2,560,381 shares of the company’s stock valued at $5,914,000 after purchasing an additional 2,485,175 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Iterum Therapeutics during the 2nd quarter valued at $207,000. Renaissance Technologies LLC bought a new position in Iterum Therapeutics during the 2nd quarter valued at $7,598,000. Sigma Planning Corp bought a new position in Iterum Therapeutics during the 2nd quarter valued at $40,000. Finally, QS Investors LLC bought a new position in Iterum Therapeutics during the 2nd quarter valued at $888,000. 6.34% of the stock is owned by hedge funds and other institutional investors.

About Iterum Therapeutics

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Read More: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.